Table 1 Characteristics of study subjects segregated according to clinical status
Characteristics | ASYM (n = 48) | CHB (n = 42) | LC (n = 49) | HCC (n = 102) | HCC with LC (n = 25) |
|---|---|---|---|---|---|
Age (years) | 36 [18–57] | 39 [20–69] | 57 [27–79] | 54.5 [26–81] | 60 [40–75] |
Gender (M/F) | 35/13 | 33/9 | 41/8 | 102/0 | 25/0 |
WBC* 109/L | 6.7 [4.8–11] | 5.99 [4.8–11.8] | 5.6 [3.2–18] | 6 [2.7–17] | 5.6 [3–8.4] |
RBC* 1012/L | 5 [3.8–47] | 4.8 [3.8–11.6] | 4.2 [2.5–5.7] | 4.5 [2.43–6] | 4 [3–5.2] |
PLT* 109/L | 227 [117–376] | 217 [117–332] | 98 [3.7–320] | 166 [40–382] | 142 [35–226] |
ALT* (IU/L) | 23 [8–74] | 47 [13–750] | 57 [13–395] | 42 [12–805] | 46 [11–290] |
AST* (IU/L) | 25 [12–35] | 38 [19–599] | 84 [15–329] | 54.5 [17–670] | 116 [25–655] |
Total bilirubin* (mg/dl) | 13 [6.7–32] | 16 [8–32] | 29 [9–571] | 18 [8–184] | 27 [9.6–185] |
Direct bilirubin* (mg/dl) | 3.5 [1–8] | 5.7 [1.4–26] | 10 [0.4–291] | 6 [1–80] | 12.5 [2–59] |
Albumin* (g/L) | 42 [38–48] | 43 [12–48] | 30 [3.3–47] | 38 [4–47] | 32 [22–42] |
Prothrombin* (% of standard) | 92 [78–127] | 94 [72–127] | 65 [23.4–92] | 78 [19.6–128] | 69 [36–124] |
HBV viral load* (copies/ml) | 6.65×104 | 5.53×105 | 8.85×105 | 5.94×105 | 4.05×105 |
[290–6.26×109] | [100–9.9×108] | [203–4.71×108] | [190–2.28×109] | [2040–3.04×109] | |
Alpha–feto protein (AFP)* (mg/L) | NA | <5 | 6.8 [1.26–300] | 79 [1.38–350] | 300 [2.56–300] |
Treatments (treated/not-treated) | Â | Â | Â | 61/41 | 15/10 |
TOCE | NA | NA | NA | 48/55 | 11/14 |
RFA | NA | NA | NA | 18/85 | 8/17 |
Alcohol injection | NA | NA | NA | 26/77 | 10/15 |
Surgery | NA | NA | NA | 6/97 | 0/25 |